



## Curriculum Vitae

Personal information **Jenny-Maria Jönsson**

### Work experience

---

1. Employer: Swedish Medical Products Agency
  - Start date: 092022
  - End date: ongoing
  - Position: Clinical Assessor
  - Activities: Clinical assessments, efficacy and safety
  - Country: Sweden
2. Employer: Region Skane/Skane University Hospital
  - Start date: 062019
  - End date: 092022
  - Position: Consultant gynaecological oncology
  - Activities: Clinical work and research
  - Country: Sweden
3. Employer: Region Skane/Skane University Hospital
  - Start date: 092016
  - End date: 062019
  - Position: Residency gynaecological oncology
  - Activities: Clinical work and research
  - Country: Sweden
4. Employer: Region Skane/Skane University Hospital
  - Start date: 092016
  - End date: 082022
  - Position: Clinical Oncologist
  - Activities: Clinical work and research
  - Country: Sweden
5. Employer: Region Skane/Skane University Hospital
  - Start date: 012009
  - End date: 092016
  - Position: Residency clinical oncology
  - Activities: Clinical work and research
  - Country: Sweden
6. Employer: Region Blekinge/Karlskrona Hospital
  - Start date: 102008
  - End date: 122008
  - Position: Temporary position at the dept. of Infectious diseases
  - Activities: Qualifying for residency
  - Country: Sweden
7. Employer: Region Blekinge/Karlskrona Hospital
  - Start date: 012007
  - End date: 102008
  - Position: Internship
  - Activities: Qualifying for license to practice medicine
  - Country: Sweden
8. Employer: Region Skane/Skane University Hospital
  - Start date: 062006
  - End date: 112006
  - Position: Temporary position at the dept. of Oncology
  - Activities: Qualifying for internship
  - Country: Sweden

### Education and training

---

1. Subject: Skane University Hospital
  - Start date: 092016
  - End date: 062019
  - Qualification: Residency/sub\_specialisation in gynaecological oncology
  - Organisation: Medical and radiation oncology incl. brachytherapy with focus on gynaecological oncology
  - Country: Sweden
2. Subject: Dept. of Gynaecology, Kliniken Essen\_Mitte, Essen
  - Start date: 092017
  - End date: 092017
  - Qualification: Qualifying for sub\_specialisation in gynaecological oncology
  - Organisation: Clinical rotation as part of residency in gynaecological oncology
  - Country: Germany
3. Subject: Skane University Hospital
  - Start date: 012009
  - End date: 092016
  - Qualification: Residency in Clinical Oncology
  - Organisation: Medical and radiation oncology
  - Country: Sweden
4. Subject: Institute for Clinical Sciences, Dept. of Oncology\_Pathology, Lund University

- Start date: 012010
  - End date: 022016
  - Qualification: Ph.D.
  - Organisation: Ph.D. studies on gene expression in epithelial ovarian cancer
  - Country: Sweden
5. Subject: Karolinska Hospital
- Start date: 012007
  - End date: 102008
  - Qualification: License to practise medicine
  - Organisation:
  - Country: Sweden
6. Subject: Ruprecht\_Karls Universität, Heidelberg
- Start date: 032005
  - End date: 072005
  - Qualification: Qualifying for University Medical Degree
  - Organisation: Exchange student, Faculty of Medicine
  - Country: Germany
7. Subject: Faculty of Medicine, Lund University
- Start date: 012001
  - End date: 062006
  - Qualification: University Medical Degree
  - Organisation:
  - Country: Sweden

## Additional information

### Publications

1. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer; Jenny\_Maria Jonsson, Maria Baath, Ida Bjornheden, Irem Durmaz Sahin, Anna Masback, Ingrid Hedenfalk; *Cancers* 2021 Jan 12;13(2):254
2. MET Expression and Cancer Stem Cell Networks Impact Outcome in High\_Grade Serous Ovarian Cancer; Maria Baath, Jenny\_Maria Jonsson, Sofia Westbom Fremer, Laura Martin de la Fuente, Lena Tran, Susanne Malander, Paivi Kannisto, Anna Masback, Gabriella Honeth, Ingrid Hedenfalk; *Genes* 2021 May 14;12(5):742
3. Crizotinib and PARP Inhibitors Act Synergistically by Triggering Apoptosis in High\_Grade Serous Ovarian Cancer; Irem Durmaz Sahin, Jenny\_Maria Jonsson, Ingrid Hedenfalk; *Oncotarget* 2019 Dec 10;10(65):6981\_6996
4. Claudin\_4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response; Laura Martin de la Fuente, Susanne Malander, Linda Hartman, Jenny\_Maria Jonsson, Anna Ebbesson, Mef Nilbert, Anna Masback, Ingrid Hedenfalk; *International Journal of Gynecologic Pathology* 2018 Mar;37(2):101\_109
5. Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma; Nicolai Skovbjerg Arildsen, Jenny\_Maria Jonsson, Katarina Bartuma, Anna Ebbesson, Sofia Westbom\_Fremer, Anna Masback, Susanne Malander, Mef Nilberg, Ingrid Hedenfalk; *Frontiers in Oncology* 2017 May 29;7:109
6. Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival; Jenny\_Maria Jonsson, Nicolai Skovbjerg Arildsen, Susanne Malander, Anna Masback, Linda Hartman, Mef Nilbert, Ingrid Hedenfalk; *Translational Oncology* 2015 Oct;8(5):424\_433
7. Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes; Jenny\_Maria Jonsson, Ida Johansson, Mev Dominguez\_Valentin, Siker Kimbung, Mats Jonsson, Jesper Hansen Bonde, Paivi Kannisto, Anna Masback, Susanne Malander, Mef Nilbert, Ingrid Hedenfalk; *PLoSOne* 2014 Sep 16;9(9):e107643
8. Distinct Gene Expression Profiles in Ovarian Cancer Linked to Lynch Syndrome; Jenny\_Maria Jonsson, Katarina Bartuma, Mev Dominguez\_Valentin, Katja Harbs, Zohreh Ketabi, Susanne Malander, Mats Jonsson, Ana Carne (2014) 13:537–54Siro, Anna Masback, Goran Jonsson, Mef Nilbert; *Familial Cancer*
9. Effect of Commercial Rye Whole\_meal Bread on Postprandial Blood Glucose and Gastric Emptying in Healthy Subjects; Joanna Hlebowicz, Jenny\_Maria Jonsson, Sandra Lindstedt, Ola Björgell, Gassan Darwich and Lars\_Olof Almér; *Nutrition Journal* 2009 Jun 16;8:26. doi: 10.1186/1475\_2891\_8\_26.

### Projects

#### Memberships

Swedish and Nordic Societies of Gynaecological Oncology Swedish Society of Oncology American Association for Clinical Research (AACR) American Society for Clinical Oncology (ASCO)

#### Other Relevant Information

Sub\_investigator in the following clinical studies:

- Athena study on advanced and recurrent ovarian cancer Sep/2019\_May/2022
- Nova study on advanced and recurrent ovarian cancer Jan/2014\_April/2021
- Ruby study on advanced and recurrent endometrial cancer Oct/2021\_March/2022
- Opinion study on recurrent ovarian cancer June/2018\_Aug/2022
- Beat study on advanced and recurrent cervical cancer Jan/2020\_Aug/2022
- "Genmab 01" on recurrent cervical cancer June/2018\_Sep/2019
- Fandango study (academic study) on recurrent and advanced endometrial cancer Aug/2017\_Dec/2019